Stress hormones cortisol and corticosterone were found to accelerate breast cancer metastasis, revealed new study.

‘Breast cancer metastases have increased activity of glucocorticoid receptors (GR) which mediate the effects of stress hormones such as cortisol.’

Because the underlying mechanisms of this phenomenon remain unclear, the research group of Prof. Mohamed Bentires-Alj from the Department of Biomedicine at the University of Basel and University Hospital of Basel has been studying the cells of a highly metastatic form of cancer known as triple-negative breast cancer. This cancer type is resistant to standard therapies leaving patients with fewer treatment options. 




Stress accelerates metastasis
To explore the heterogeneity between tumors and metastases, the researchers profiled the activity of genes in a mouse model of breast cancer.
Concentrations of the stress hormones cortisol and corticosterone were higher in mice with metastases that in those with no metastases. The scientists show that increased levels of these stress hormones activate the GR, which cause increased colonization and heterogeneity of the cancer cells - and ultimately, shortened survival.
Reduced efficacy of chemotherapy
Advertisements
These findings suggest that caution should be taken when prescribing glucocorticoid hormones to patients with breast cancer. The study also suggests that GR inhibition may be beneficial for patients and could lead to the development of new therapies to combat breast cancer metastasis. "Tumor heterogeneity is a serious hurdle for therapy. These findings highlight the importance of stress management in patients - and especially those with triple-negative breast cancer," states Prof. Bentires-Alj. "Moderate exercise and relaxation techniques have been shown to correlate with enhanced quality of life and greater survival in patients."
Advertisements
The Basel Breast Consortium was initiated in 2014 by Prof. Mohamed Bentires-Alj and Prof. Walter Paul Weber, Chief Physician Department of Breast Surgery at the University Hospital Basel. It has more than 160 researchers and clinicians from academia and industry as well as patient advocates, committed to promoting research and translating basic science into leading-edge breast cancer clinical studies.
Source-Eurekalert